Clinical Data for AMITIZA(R) Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting
13 oct. 2014 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for AMITIZA®...
Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA
09 oct. 2014 16h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Sucampo, R-Tech Ueno, Ltd. (RTU), Takeda...
Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation
29 sept. 2014 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) and its development and commercialization partner, Takeda Pharmaceuticals (Takeda), today...
Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone
21 août 2014 16h30 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that its subsidiary, Sucampo AG, has signed...
Sucampo Announces Publication of NICE Recommendation for AMITIZA(R) (Lubiprostone)
23 juil. 2014 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Maryland and ABINGDON, Oxfordshire, July 23, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the...
AMITIZA(R) (Lubiprostone) Receives NICE Recommendation
17 juin 2014 20h06 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., June 17, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the United Kingdom's (U.K.) National...
Sucampo Issues Statement Regarding Anesthetic and Analgesic Drug Products Advisory Committee Meeting's Vote
12 juin 2014 14h41 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., June 12, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today issued the following statement regarding the...
Sucampo and Takeda Announce Update on Liquid Formulation Program for AMITIZA(R) (lubiprostone)
14 mars 2014 17h29 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., March 14, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharma Americas, LLC, a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), and its development and...
Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
12 mars 2014 20h00 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., March 12, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) today announced that Sucampo Pharma Europe, Ltd., its wholly owned subsidiary, has received a...
Sucampo and Takeda Initiate Pivotal Trial of Lubiprostone Liquid Formulation in Adults With Chronic Idiopathic Constipation
23 oct. 2013 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md. and DEERFIELD, Ill., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals...